Clinical Trial: An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07117630) titled 'An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy' on July 29.

Brief Summary: This is a prospective, open-label, Bayesian adaptive Phase 2 clinical trial evaluating the efficacy and safety of a novel triple-combination therapy (Dalpiciclib + Fulvestrant + L-Ornithine L-Aspartate) in patients with HR-positive/HER2-negative advanced breast cancer (ABC) who have progressed on prior standard therapy including CDK4/6 inhibitors and endocrine therapy.

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: L-...